Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...
Investor's Business Daily on MSN
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback